CytoDyn to Present at Wall Street Reporter’s Livestream Event on July 9, 2020 at 1:30 pm ET / 10:30 am PT
VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, and Scott Kelly, M.D., Chief Medical Officer of CytoDyn, will provide a comprehensive business and clinical trials update. The Wall Street Reporter’s event is scheduled for Thursday, July 9, 2020 at 1:30 pm ET / 10:30 am PT. The presentation will be approximately 15 minutes followed by a Q&A session of approximately 45 minutes.